Circulating tumor cells (CTCs) are tumor cells that shed from the primary tumor and
intravasate into the peripheral blood circulation system responsible for metastasis. Sensitive …

Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …

Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …

Circulating tumor cells (CTCs) are the seeds of distant metastasis, and the number of CTCs
detected in the blood of cancer patients is associated with a worse prognosis. CTCs face …

The mutational and phenotypic landscape of tumors is dynamic, requiring constant
monitoring of cancer patients to provide the most up-to-date and effective care. Circulating …

Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans
and its incidence continues to rise. Although CSCC usually display a benign clinical …

Introduction Programmed death-ligand 1 (PD-L1) expression may vary in different disease
sites and at different time points of the disease course. We aimed to investigate PD-L1 …

Immune checkpoint inhibitors have transformed the prognosis and treatment paradigm of
many cancer types, through the potential for durable responses. However, the majority of …

The emergence of immunotherapy in oncology requires the discovery, validation and
subsequent adoption of robust, sensitive and specific predictive and prognostic biomarkers …

Commonly, circulating tumor cells (CTCs) are described as source of metastasis in cancer
patients. However, in this process cancer cells of the primary tumor site need to survive the …